European urology oncologyHumansMaleProstatic NeoplasmsGonadotropin-Releasing HormoneAged
Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial.
Thomas Zilli, Dirk Böhmer, Andreas Roeder, David Lauffer, Ana Elena Villafranca Iturre, Josep Jové Jové-Teixidó, Stéphane Supiot, Igor Latorzeff, Piet Dirix, François-Xavier Otte, Giulio Francolini, Thierry Roumeguère, Jean Marc Simon, Beatrice Fournier, Catherine Fortpied
Published: 202510.1016/j.euo.2025.10.009
Abstract
BACKGROUND AND OBJECTIVE: External beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy (ADT) is standard for high-risk prostate cancer. EORTC 1414 compared ADT with a luteinizing hormone-releasing hormone (LHRH) antagonist (…
Preview only. Read the full abstract at the source